VIA-2291

DRUG3 trials

Sponsors

Tallikut Pharmaceuticals, Inc.

Conditions

Acute Coronary SyndromeAtherosclerosisCoronary Artery Disease

Phase 2

Study Effect of VIA-2291 on Atherosclerotic Vascular Inflammation in Patients Undergoing Elective Carotid Endarterectomy

CompletedNCT00352417

Tallikut Pharmaceuticals, Inc.Atherosclerosis

Start: 2006-07-31End: 2008-07-31Updated: 2012-07-27

Study Effect of VIA-2291 on Vascular Inflammation

CompletedNCT00358826

Tallikut Pharmaceuticals, Inc.Coronary Artery Disease

Start: 2006-07-31End: 2008-09-30Updated: 2012-07-23

Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event

CompletedNCT00552188

Tallikut Pharmaceuticals, Inc.Acute Coronary Syndrome

Start: 2007-10-31End: 2009-11-30Updated: 2013-08-09

Related Papers

Effect of 5-lipoxygenase inhibitor, VIA-2291 (Atreleuton), on epicardial fat volume in patients with recent acute coronary syndrome.

2020-01-179 citations

Effect of treatment with 5‐lipoxygenase inhibitor <scp>VIA</scp>‐2291 (atreleuton) on coronary plaque progression: a serial <scp>CT</scp> angiography study

Clinical Cardiology2016-11-2441 citations

Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome.

2010-02-27103 citations